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Example of patient QA: Varian Trilogy linac with HD120 MLC, 
VMAT delivery technique (lung tumor), 15 MV beam quality, 
~6 Gy overall dose. 
Conclusions: The technology has been proven to be valuable 
for patient plan quality assurance of complex fields through 
an extensive clinical investigation considering different 
irradiation techniques. High dosimetric performance was 
achieved in the verification of therapy beams due to high 
spatial resolution, insensitivity on dose per pulse and energy 
independence. The new ionization chamber technology is 
intended to be used in future 2D detectors.  
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Purpose/Objective: Low energy proton beam could be of 
potential interest for radiation treatments of shallow lesions 
due to expected higher relative biological effectiveness (RBE) 
and sharp dose fall-off beyond target volume. We designed 
and performed output measurements for RBE using EBT3 
model GafChromicTM film. 
Materials and Methods: Figure 1.a represents experimental 
setup used to measure depth dose curve (Fig.1.b) and beam 
output using a calibrated PTW Markus ion chamber. To 
improve stability of irradiation beam (26.5 MeV protons) from 
cyclotron CS30, an aluminum cylinder was added in front of 
the beam serving as a timed shutter. As beam's energy 
decreases with depth, measurement depth was scaled using 
ratio of continuous slowing down approximation (CSDA) 
ranges at each point. Measured signal, corrected by monitor 
chamber reading, was scaled by ratio of stopping powers at a 
given depth for water and air divided by the same ratio in 
Cobalt. Output was measured at 3 mm depth in the middle of 
plateau ahead of the Bragg peak, and PDD was normalized at 
the same depth. Following the TRS398 reference dosimetry 
protocol for proton beams, output was measured in water in 
terms of Gy/nC where nC is reading of the monitor chamber. 
Once the output was known, we calibrated EBT3 film model 
for doses up to 35 Gy (Fig.1.c) by irradiating film pieces in 
Solid WaterTM at depth of 3 mm and converting depth to 
water. For RBE determination, attached breast cell cultures 
(MCF-7, MCF-12, MDA-MB-231) in 96-well plates were 
irradiated by the horizontal beam (Fig.1.d). Behind the plate, 
a piece of film was placed to monitor dose distribution during 
experiment. The MTT colorimetric dye assay was used to 
assess cell survival (proliferation inhibition) following 
irradiation. 
Results: Depending on the cyclotron current and collimator 
to surface distance (CSD), outputs ranged approximately from 
6.8 Gy/s (10 nA, 165 cm CSD) to 500 Gy/s (100 nA, 75 cm 
CSD). For each irradiated 96-well plate, a dose image was 
reconstructed (Fig.1.e) and then scaled by the measured PDD 
data. Natural Gaussian shape of the beam was used to obtain 
multiple dose points within the plate from single exposure. 
Average doses (per well) were used to construct the survival 
fraction (Fig.1.f). The average RBE of proton beam compared 
to x-ray at the 50% inhibitory dose was 1.22 (SD = 0.05), 
which was statistically higher (P = 0.02) than the 1.1 
reported for standard proton therapy. 
Conclusions: We described a radiochromic film-based dose 
monitoring system that can be used for colorimetric 
radiobiology assays with low energy proton beams. The 
relatively higher RBE would be promising for treatment of 
low laying lesions. Having a sharp dose fall-off behind the 
Bragg peak, high dose rate proton beam originating from a 
production cyclotron could further allow for dose escalation 
protocols in the case of superficial diseases or during intra-
operative radiotherapy procedures. Supported by NSTIP 11-
BIO1428-20. 
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Purpose/Objective: To investigate the feasibility of back-
projection portal dosimetry for accurate in vivo 3D 
dosimetric verification of Volumetric Modulated Arc Therapy 
(VMAT) prostate treatments by an EPID gantry angle-resolved 
data acquisition, throught the calculation of patient 
transmission. 
The novel approach is analysing data by dose volume 
histograms (DVH), that provide information on actual 
delivered dose to the tumor volume and surrounding critical 
structures. 
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Materials and Methods: In the instance of transit dosimetry, 
the EPID creates a fluence map and converts this to dose 
delivered via calibration of the EPID image using an 
appropriate customised algorithm (Dosimetry Check, Math 
Resolutions LLC), for each angular sector gantry angle. 
The delivered dose is reconstructed from the deposited 
energy fluence in each voxel of the planning volumetric 
dataset CT after correcting for attenuation coefficients.  
Twenty prostate cases treated by VMAT are analysed. 
Treatments are delivered using a Varian 2100CD linear 
accelerator's 6 MV x-ray beam and a Varian 120 Dynamic 
MultiLeaf Collimator. Fluences are acquired on a Varian 
aSi1000 EPID. The Varian Eclipse treatment planning system 
is used to planning RapidArc prostate treatments in a single 
arc delivery. 
Pretreatment patient-specific quality assurance is previously 
performed using local 3% 3 mm gamma criterion to detect 
technical sources of systematic error. 
2D dose distributions, point doses, gamma distributions (with 
3% 3mm criterion), three orthogonal slices through the EPID-
reconstructed dose distribution and DVH statistics are 
estimated from the first fraction of the VMAT treatment. 
Results: Absolute differences of Isocenter Point doses 
between in vivo dosimetry and Eclipse calculation are within 
3% (min 0,6%-max 5,4%). Volume and area in sagittal, axial 
and coronal plane through the isocenter with gamma < 1 are 
reported. . Planned DVH parameters were compared with in-
vivo results: median dose (D50), near-maximum dose (D2) 
and near-minimum dose (D98) in PTV. OAR significant values 
were also compared. 
One case was excluded from statistics because very poor 
match was observed between prediction and measurement 
during the transit dosimetry session. Further investigation 
attributed this to internal anatomic changes and a replanning 
was constructed. 
Conclusions: Gamma passing rate, even if calculated based 
on patient dose grids, has generally weak correlation to 
critical patient DVH errors. Using patient-DVH-based metrics 
VMAT QA allows per-patient dose in vivo QA to be based on 
metrics that are both sensitive and specific. 
In particular, DVH analysis can achieve correlation between 
deviations from calculations and anatomical dose 
measurements. 
Further studies are now required to analyze new processes 
and action levels associated. 
 
 
Poster Discussion: Young Scientists 6: Treatment planning 
calculation, optimization, Radiobiological planning, 
predictive models of outcome  
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Purpose/Objective: Several studies comparing Acuros XB 11 
(Varian Eclipse TPS) with Monte Carlo simulations showed 
that Acuros XB is more accurate in predicting the dose in 
inhomogeneous media compared to convolution algorithms. 
Since our clinical experience is based on dose distributions 
obtained with convolution algorithms, it is still unclear how 
Acuros should be implemented in the clinical routine and how 
to interpret the different dose distributions clinically. We 
have evaluated the difference in dose between the Acuros 
algorithm scored in water (AcurosWater: Dw), the Acuros 
algorithm scored in medium (AcurosMedium: Dm) and the 
AAA 11 algorithm (Varian Eclipse) implicitely scored in water 
for various treatment sites with particular emphasis to the 
differences in the dose distribution in high density tissues, 
e.g. bone. 
Materials and Methods: 32 volumetric modulated arc therapy 
treatment plans (5 sarcoma, 5 prostate, 8 thorax, 8 
intracranial, 6 spinal cord lesions) were recalculated using 
AAA, AcurosWater and AcurosMedium and the dose 
distributions to the planning target volume (PTV) and gross 
tumor volume (GTV) were compared. Additionally mean dose 
differences of various organs at risk (OAR) divided into three 
groups (lung tissue, soft tissue and bone) were analyzed. 
Results: The median deviations of the PTV and GTV mean 
dose for all the treatment sites were within 1.3%, whereas 
the deviation of PTV minimum and maximum dose were up to 
37%. Looking at individual plans we observed that the dose 
distribution calculated with Acuros was more inhomogeneous 
compared to AAA and the dose calculated in bony structures 
was generally lower for AAA compared to AcurosWater and 
slightly higher for AcurosMedium. For example the dose 
distribution for the treatment of vestibular schwannomas 
showed a median deviation of minimum and maximum dose 
for the PTV (Dw, Dm) of (-11.9%, -13.5%) and (4.7%, -2.1%) 
AcurosWater calculated a dose higher and AcurosMedium 
lower than the prescribed dose to large parts of the bone 
(Figure1). The median difference in dose to the OARs were 
for lung below (-1.6%, -1.8%), for soft tissue below (-0.9%, -
2.0%) and in bone (2%, -2.2%). 
Conclusions: The mean dose to PTV and GTV showed small 
deviations (less than 1.3 %). However dose calculated with 
Acuros in heterogeneous medium was more inhomogeneous 
compared to AAA. In bone it showed a large difference which 
should not be neglected when changing the dose calculation 
algorithm from AAA to Acuros. The physicians need to get 
used to the more inhomogeneous dose distributions in the 
PTV and an increased dose to bony structures. 
 
Figure 1: Example of a dose distribution for a vestibular 
schwannoma treatment; AcurosWater calculated in bone a 
dose 8% higher than the prescribed dose (36 Gy) and 5% lower 
with AcurosMedium 
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Purpose/Objective: Simulation of biological effects induced 
on DNA by ionizing radiation is an active field of research in 
which the study of ionization cluster size distributions (ICS) is 
a useful tool for calculating the number and complexity of 
